Related scientific articles (all)

Marginal zone lymphomas: second most common lymphomas in older patients.

Authors : Bron D, Meuleman N
Year : 2019
Journal : Curr Opin Oncol
Volume : 31
Pages : 386-393

Multicultural approaches of cancer pain.

Authors : Crombez P, Bron D, Michiels S
Year : 2019
Journal : Curr Opin Oncol
Volume : 31
Pages : 268-274

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.

Authors : Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, Béné MC, Broijl A, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Garderet L, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Lenain P, Macro M, Mathiot C, Orsini-Piocelle F, Perrot A, Stoppa AM, van de Donk NW, Wuilleme S, Zweegman S, Kolb B, Touzeau C, Roussel M, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Fermand JP, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Zhuang S, Chiu C, Pei L, de Boer C, Smith E, Deraedt W, Kampfenkel T, Schecter J, Vermeulen J, Avet-Loiseau H, Sonneveld P
Year : 2019
Journal : Lancet
Volume : 394
Pages : 29-38

Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers.

Authors : Rossi C, Gilhodes J, Maerevoet M, Herbaux C, Morschhauser F, Brice P, Garciaz S, Borel C, Ysebaert L, Obéric L, Lazarovici J, Deau B, Dupuis J, Chauchet A, Abraham J, Bijou F, Stamatoullas-Bastard A, Malfuson JV, Golfier C, Laurent C, Pericart S, Traverse-Glehen A, Kanoun S, Filleron T, Casasnovas RO, Ghesquières H
Year : 2018
Journal : Am J Hematol

Are we ready for intercultural cancer care?

Authors : Crombez P, Michiels S, Bron D
Year : 2018
Journal : Curr Opin Oncol
Volume : 30(4)
Pages : 205-211

Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial).

Authors : Rahmé R, Ades L, Thomas X, Guerci-Bresler A, Pigneux A, Vey N, Raffoux E, Castaigne S, Spertini O, Wittnebel S, Marolleau JP, Damaj G, Bordessoule D, Lejeune J, Chevret S, Fenaux P
Year : 2018
Journal : Haematologica
Volume : 103
Pages : e519-e521

Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation.

Authors : Fostier K, Caers J, Meuleman N, Broos K, Corthals J, Thielemans K, Schots R, De Keersmaecker B
Year : 2018
Journal : Oncotarget
Volume : 9
Pages : 20476-20489

Long-term follow-up of 2 patients treated with 90Y-rituximab radioimmunotherapy for relapse of nodular lymphocyte-predominant Hodgkin lymphoma.

Authors : Golstein SC, Muylle K, Vercruyssen M, Spilleboudt C, de Wind A, Bron D
Year : 2018
Journal : Eur J Haematol
Volume : 101
Pages : 415-417

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Authors : Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, dHollander K, Pantel K
Year : 2018
Journal : J Natl Cancer Inst
Volume : 110(6)
Pages : 560-567

Dual JAK1 and STAT3 mutations in a breast implant-associated anaplastic large cell lymphoma.

Authors : Letourneau A, Maerevoet M, Milowich D, de Wind R, Bisig B, Missiaglia E, de Leval L
Year : 2018
Journal : Virchows Arch
Volume : 473
Pages : 505-511

Advanced Glycation End-Products-, C-Type Lectin- and Cysteinyl/ Leukotriene-Receptors in Distinct Mesenchymal Stromal Cell Populations: Differential Transcriptional Profiles in Response to Inflammation.

Authors : Najar M, Fayyad-Kazan M, Raicevic G, Fayyad-Kazan H, Meuleman N, Bron D, Lagneaux L
Year : 2018
Journal : Cell J
Volume : 20
Pages : 250-258

Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.

Authors : Zardavas D, Te Marvelde L, Milne RL, Fumagalli D, Fountzilas G, Kotoula V, Razis E, Papaxoinis G, Joensuu H, Moynahan ME, Hennessy BT, Bieche I, Saal LH, Stal O, Iacopetta B, Jensen JD, OToole S, Lopez-Knowles E, Barbaraeschi M, Noguchi S, Azim HA Jr, Lerma E, Bachelot T, Wang Q, Perez-Tenorio G, Can de Velde CJH, Rea DW, Sabine V, Bartlett JMS, Sotiriou C, Michiels S, Loi S
Year : 2018
Journal : J Clin Oncol
Volume : 36(10)
Pages : 981-990

Multidisciplinary development of the Geriatric Core Dataset for clinical research in older patients with cancer: A French initiative with international survey.

Authors : Paillaud E, Soubeyran P, Caillet P, Cudennec T, Brain E, Terret C, Etchepare F, Mourey L, Aparicio T, Pamoukdjian F, Audisio RA, Rostoft S, Hurria A, Bellera C, Mathoulin-Pélissier S, + collaborators (among others :, Bron D
Year : 2018
Journal : Eur J Cancer
Volume : 103
Pages : 61-68

Immunological impact of Wharton's Jelly mesenchymal stromal cells and natural killer cell co-culture.

Authors : Najar M, Fayyad-Kazan M, Meuleman N, Bron D, Fayyad-Kazan H, Lagneaux L
Year : 2018
Journal : Mol Cell Biochem
Volume : 447(1-2)
Pages : 111-124

Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies.

Authors : Cabannes-Hamy A, Peyrade F, Jardin F, Emile JF, Delwail V, Mounier N, Haioun C, Perrot A, Fitoussi O, Lara D, Delarue R, André M, Offner F, Ghesquières H, Pascal L, Soussain C, Lazarovici J, Schiano JM, Gaulard P, Tilly H, Thieblemont C, + collaborators (among others :, Maerevoet M
Year : 2018
Journal : Cancer Med
Volume : 7
Pages : 539-548

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.

Authors : Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes Da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA, + collaborators (among others :, Bron D
Year : 2018
Journal : N Engl J Med
Volume : 379
Pages : 934-947

Mesenchymal stromal cells of the bone marrow and natural killer cells: cell interactions and cross modulation.

Authors : Najar M, Fayyad-Kazan M, Meuleman N, Bron D, Fayyad-Kazan H, Lagneaux L
Year : 2018
Journal : J Cell Commun Signal
Volume : 12(4)
Pages : 673-688

Insights into inflammatory priming of mesenchymal stromal cells: functional biological impacts.

Authors : Najar M, Krayem M, Merimi M, Burny A, Meuleman N, Bron D, Raicevic G, Lagneaux L
Year : 2018
Journal : Inflamm Res
Volume : 67(6)
Pages : 467-477

Immunohematology Mesenchymal Stromal Cell-based Therapy: From Research to Clinic.

Authors : Najar M, Krayem M, Meuleman N, Bron D, Hélène B, Lagneaux L
Year : 2018
Journal : Appl Immunohistochem Mol Morphol
Volume : 26(3)
Pages : e26-e43

Steps forward for cancer precision medicine.

Authors : Salgado R, Moore H, Martens JWM, Lively T, Malik S, McDermott U, Michiels S, Moscow JA, Tejpar S, McKee T, Lacombe D
Year : 2018
Journal : Nat Rev Drug Discov
Volume : 17(1)
Pages : 1-2